menu
    • menu
    [{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hasten Biopharmaceutic","amount2":0.32000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.32000000000000001,"dosageForm":"Tablet","sponsorNew":"Hasten Biopharmaceutic \/ CBC Group","highestDevelopmentStatusID":"12","companyTruncated":"Hasten Biopharmaceutic \/ CBC Group"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"LIB Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Lerodalcibep","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Hasten Biopharmaceutic","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.33000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lerodalcibep","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"12","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"14","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"}]

    Find Clinical Drug Pipeline Developments & Deals by Hasten Biopharmaceutic

    Menu

    Hasten Biopharmaceutic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion

                            Details : Through the acquisition, Hasten will own the Marketing Authorisation Holder rights of products in 8 countries, which includes Edarbi (azilsartan medoxomil) indicated for the treatment of hypertension.

                            Brand Name : Edarbi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 02, 2024

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion

                            Details : Through this acquisition, Hasten leverages commercial rights to treatments for various chronic disease, which include the approved product Edarbi (azilsartan medoxomil), indicated for hypertension.

                            Brand Name : Edarbi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 28, 2024

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : LIB Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LIB Therapeutics and Hasten Announce Acceptance of Lerodalcibep Clinical Trial Application

                            Details : LIB003 (lerodalcibep) is a potential best in class, novel, small binding protein, third-generation PCSK9 inhibitor, which is being evaluated for the treatment and prevention of cardiovascular disease.

                            Brand Name : LIB003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 19, 2024

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : LIB Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : LIB Therapeutics

                            Deal Size : $325.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop...

                            Details : Under the terms of the agreement, LIB has granted Hasten the exclusive rights to develop and commercialize LIB003 (lerodalcibep), a next-generation, PCSK9 inhibitor, for patients at very high and high-risk of cardiovascular disease, in Greater China.

                            Brand Name : LIB003

                            Molecule Type : Large molecule

                            Upfront Cash : $20.0 million

                            September 12, 2023

                            Lead Product(s) : Lerodalcibep

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : LIB Therapeutics

                            Deal Size : $325.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : CBC Group

                            Deal Size : $315.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma

                            Details : The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, ...

                            Brand Name : Edarbi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 20, 2023

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : CBC Group

                            Deal Size : $315.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth